Publications

Academic publications

2023

  • Arbyn M, Costa S, Latsuzbaia A, et al. HPV-based Cervical Cancer Screening on Self-samples in the Netherlands: Challenges to Reach Women and Test Performance Questions. Cancer Epidemiol Biomarkers Prev. 2023;32:159–63.
  • Arbyn M, Cuschieri K, Poljak M, et al. Can REALQUALITY RQ-HPV screen be considered as a clinically validated HPV test for use in cervical cancer screening? Clinical Microbiology and Infection. 2023. Available from: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(23)00403-2/abstract
  • Brentnall AR, Cuschieri K, Sargent A, et al. Staged design recommendations for validating relative sensitivity of self-sample human papillomavirus tests for cervical screening. J Clin Epidemiol. 2023;166:111227.
  • Cocuzza CE, Dhillon SK, Martinelli M, et al. Clinical performance of the novel full‐genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework. Intl Journal of Cancer. 2023;ijc.34754.
  • Cuschieri K, Fellner MD, Arroyo Mühr LS, et al. Quality assurance in human papillomavirus testing for primary cervical screening. Int J Gynecol Cancer. 2023;33:802–11.
  • Dhillon SK, Chung PYJ, Padalko E, et al. Intra- and interlaboratory reproducibility of the RIATOL qPCR HPV genotyping assay. J Med Virol. 2023;95:e29093.
  • Dovnik A, Poljak M. The Role of Methylation of Host and/or Human Papillomavirus (HPV) DNA in Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Lesions. International Journal of Molecular Sciences. 2023;24:6479.
  • Downham L, Jaafar I, Rol ML, et al. Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis. Br J Cancer. 2023;1–9.
  • Glinska P, Komerska K, Janik B, et al. HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)—study protocol of a randomised healthcare policy trial. BMC Cancer. 2023;23:1118.
  • Hall MT, Simms KT, Murray JM, et al. Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV. Nat Med. 2023;29:3059–66.
  • Latsuzbaia A, Keer SV, Broeck DV, et al. Clinical Accuracy of Alinity m HR HPV Assay on Self- versus Clinician-Taken Samples Using the VALHUDES Protocol. The Journal of Molecular Diagnostics. 2023;25:957–66.
  • Latsuzbaia A, Vanden Broeck D, Van Keer S, et al. Comparison of the Clinical Accuracy of Xpert HPV Assay on Vaginal Self-Samples and Cervical Clinician-Taken Samples within the VALHUDES Framework. The Journal of Molecular Diagnostics. 2023;25:702–8.
  • Mlakar J, Oštrbenk Valenčak A, Kežar J, et al. Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia. Vaccines. 2023;11:423.
  • Pimenoff VN, Gray P, Louvanto K, et al. Ecological diversity profiles of non-vaccine-targeted HPVs after gender-based community vaccination efforts. Cell Host & Microbe. 2023;31:1921-1929.e3.
  • Poljak M, Cuschieri K, Alemany L, et al. Testing for Human Papillomaviruses in Urine, Blood, and Oral Specimens: an Update for the Laboratory. J Clin Microbiol. 2023;e01403-22.
  • Simms KT, Keane A, Nguyen DTN, et al. Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population. Nat Med. 2023;29:3050–8.
  • Verhoef L, Bleeker MCG, Polman N, et al. Evaluation of DNA methylation biomarkers ASCL1 and LHX8 on HPV-positive self-collected samples from primary HPV-based screening. Br J Cancer. 2023;129:104–11.
  • Wang J, Elfström KM, Lagheden C, et al. Impact of cervical screening by human papillomavirus genotype: Population-based estimations. PLOS Medicine. 2023;20:e1004304.
  • Yilmaz E, Eklund C, Lagheden C, et al. First international proficiency study on human papillomavirus testing in cervical cancer screening. Journal of Clinical Virology. 2023;167:105581.

2022

  • Arbyn M, Bonde J, Cushieri K, Poljak M. Can HPV Selfy be considered as a clinically validated HPV test for use in cervical cancer screening? Journal of Translational Medicine. 2022a Sep 16;20(1):422.
  • Arbyn M, Latsuzbaia A, Castle PE, Sahasrabuddhe VV, Broeck DV. HPV testing of self-samples: Influence of collection and sample handling procedures on clinical accuracy to detect cervical precancer. The Lancet Regional Health – Europe [Internet]. 2022b Mar 1 [cited 2022 Feb 22];14. Available from: https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(22)00025-4/fulltext
  • Arroyo Mühr LS, Eklund C, Lagheden C, Eriksson T, Pimenoff VN, Gray P, et al. Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses. J Infect Dis. 2022 Sep 28;226(7):1195–9.
  • Athanasiou A, Veroniki AA, Efthimiou O, Kalliala I, Naci H, Bowden S, et al. Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis. The Lancet Oncology. 2022 Aug 1;23(8):1097–108.
  • Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. The Lancet Global Health. 2022 Aug;10(8):e1115–27.
  • Fernández-Deaza G, Caicedo-Martinez M, Serrano B, Roura E, Castillo JS, Sanjose S de, et al. Cervical cancer screening programs in Latin America: current recommendations for facing elimination challenges. salud publica mex. 2022 64/4;64(4):415–23.
  • Heideman DAM, Oštrbenk Valenčak A, Doorn S, Bonde J, Hillemanns P, Gimpelj Domjanič G, et al. Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening. Viruses. 2022 May;14(5):893.
  • Inturrisi F, Berkhof J. Pricing of HPV tests in Italian tender-based regional settings. Journal of Medical Economics. 2022 May 26;1–21.
  • Inturrisi F, Bogaards JA, Siebers AG, Meijer CJLM, Heideman DAM, Berkhof J. Women with a positive high-risk human papillomavirus (HPV) test remain at increased risk of HPV infection and cervical precancer ≥15 years later. Tumour Virus Research. 2022a Dec 1;14:200240.
  • Inturrisi F, Rozendaal L, Veldhuijzen NJ, Heideman DAM, Meijer CJLM, Berkhof J. Risk of cervical precancer among HPV–negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study. PLOS Medicine. 2022b Oct 28;19(10):e1004115.
  • Kelly H, Jaafar I, Chung M, Michelow P, Greene S, Strickler H, et al. Diagnostic accuracy of cervical cancer screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: A systematic review and meta-analysis. eClinicalMedicine. 2022 Nov 1;53:101645.
  • Latsuzbaia A, Vanden Broeck D, Van Keer S, Weyers S, Tjalma WAA, Doyen J, et al. Clinical Performance of the RealTime High Risk HPV Assay on Self-Collected Vaginal Samples within the VALHUDES Framework. Microbiology Spectrum. 2022 Sep;0(0):e01631-22.
  • Lefeuvre C, De Pauw H, Le Duc Banaszuk AS, Pivert A, Ducancelle A, Rexand-Galais F, et al. Study Protocol: Randomised Controlled Trial Assessing the Efficacy of Strategies Involving Self-Sampling in Cervical Cancer Screening. Int J Public Health. 2022 Feb 24;67:1604284.
  • Nyaga VN, Arbyn M. Metadta: a Stata command for meta-analysis and meta-regression of diagnostic test accuracy data – a tutorial. Archives of Public Health. 2022 Mar 29;80(1):95.
  • Pedersen H, Ejegod DM, Quint W, Xu L, Arbyn M, Bonde JH. Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework. The Journal of Molecular Diagnostics [Internet]. 2022 Feb 3 [cited 2022 Feb 22]; Available from: https://www.sciencedirect.com/science/article/pii/S1525157822000174
  • Ritchie D, Arbyn M, Basu P, Corbex M, Fidarova E, Ivanuš U, et al. Europe’s Path to Eliminating Cervical Cancer as a Public Health Problem. The Lancet Regional Health – Europe [Internet]. 2022 Jan 1 [cited 2021 Dec 10];12. Available from: https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00262-3/fulltext#seccesectitle0004
  • Serrano B, Ibáñez R, Robles C, Peremiquel-Trillas P, de Sanjosé S, Bruni L. Worldwide use of HPV self-sampling for cervical cancer screening. Preventive Medicine. 2022 Jan;154:106900.
  • Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. The Lancet Global Health [Internet]. 2022 Dec 14 [cited 2023 Jan 9]; Available from: https://www.sciencedirect.com/science/article/pii/S2214109X22005010
  • Smith MA, Sherrah M, Sultana F, Castle PE, Arbyn M, Gertig D, et al. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. BMJ. 2022 Mar 30;376:e068582.
  • Taumberger N, Joura EA, Arbyn M, Kyrgiou M, Sehouli J, Gultekin M. Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee. Int J Gynecol Cancer. 2022 Oct;32(10):1316–20.
  • Zhang L, Carvalho AL, Mosquera I, Wen T, Lucas E, Sauvaget C, et al. An international consensus on the essential and desirable criteria for an ‘organized’ cancer screening programme. BMC Medicine. 2022 Mar 23;20(1):101.

2021

  • Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P, Kelly D, Poljak M, Bergeron C, Ritchie D, Schmidt D, Kyrgiou M, Van den Bruel A, Bruni L, Basu P, Bray F, Weiderpass E. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer. 2021 Jan 15;148(2):277-284. doi: 10.1002/ijc.33189.
  • Arbyn M, Simon M, Peeters E, Meijer CJLM, Berkhof J, Cuschieri K, Bonde J, Oštrbenk Valenčak A, Zhao F-H , Rezhake R, Gultekin M, Dillner J, de Sanjosé S, Canfell K, Hillemanns P, Almonte M, Xu L, Wentzensen N, Poljak M. 2020 List of human papillomavirus assays Suitable for primary cervical cancer screening. Clin Microbiol Infect 2021 May 8;S1198-743X(21)00219-6. doi: 10.1016/j.cmi.2021.04.031
  • Bhatia R, Boada EA, Bonde JH, Quint WGV, Xu L, Ejegod DM, et al. Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework. J Clin Pathol [Internet]. 2021 Nov 14 [cited 2021 Nov 20]; Available from: https://jcp.bmj.com/content/early/2021/11/14/jclinpath-2021-207864
  • Bonjour M, Charvat H, Franco EL, Piñeros M, Clifford GM, Bray F, Baussano I. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. Lancet Public Health. 2021 Jul;6(7):e510-e521. doi: 10.1016/S2468-2667(21)00046-3.
  • Chargari C, Arbyn M, Leary A, Abu-Rustume NR, Basu P, Bray F, Chopra S, Nout R, Tanderup K, Viswanathan AC, Zacharopoulou C, Soria JC, Deutsch E, Gouy S, Morice P. Increasing global accessibility to high-level treatments for cervical cancers. Gynecologic Oncology 2021. doi: https://doi.org/10.1016/j.ygyno.2021.10.073
  • Dhillona SK, Oštrbenk Valenčak A, Xu L, Poljak M, Arbyn M, Clinical and analytical evaluation of the Alinity m HR HPV 2 assay within the VALGENT-3 framework. J Clin Microbiol. 2021 Mar 17;JCM.00286-21. doi: 10.1128/JCM.00286-21
  • Dick S, Vink FJ, Heideman D, Lissenberg-Witte BI, Meijer CJLM, Berkhof J, Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping. British Journal of Cancer 2021. doi: 10.1038/s41416-021-01614-4
  • Ejegod DM, Pedersen H, Pedersen BT, Jonassen CM, Lie AK, Hulleberg LS, Arbyn M, Bonde J. Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program. Am J Clin Pathol. 2021 Sep 21:aqab138. doi: 10.1093/ajcp/aqab138
  • Ejegod DM, Pedersen H, Quint W, Xu L, Arbyn M, Bonde JH. Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework. J Virol Methods. 2021b Jun 1;292:114118.
  • Gray P, Kann H, Pimenoff VN, Eriksson T, Luostarinen T, Vänskä S, Surcel HM, Faust H, Dillner J, Lehtinen M. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. PLoS Med. 2021 Jun 7;18(6):e1003588. doi: 10.1371/journal.pmed.1003588.
  • Hamers FF, Poullié AI, Arbyn M. Updated evidence-based recommendations for cervical cancer screening in France. Eur J Cancer Prev [Internet]. 2021 Jul 20 [cited 2021 Aug 10]; Available from: https://journals.lww.com/eurjcancerprev/Abstract/9000/Updated_evidence_based_recommendations_for.99034.aspx
  • Hautekiet J, Arbyn M, Prigge E, Obermueller T, Goetghebeur E. A framework for meta-analysis through standardized survival curves. 2111.13132.pdf (arxiv.org)
  • Inturrisi F, Aitken CA, Melchers WJG, van den Brule AJC, Molijn A, Hinrichs JWC, Niesters HGM, Siebers A, Schuurman R, Heideman DAM, de Kok IMCM, Bekkers RLM, van Kemenade FJ, Berkhof J. Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: An observational study. The Lancet Regional Health - Europe 2021. doi: doi.org/10.1016/j.lanepe.2021.100235
  • Obermueller T, Hautekiet J, Busto MP, Reynders D, Belgioia L, Cats A, Gilbert DC, Koerber SA, Mai S, Meulendijks D, Rödel F, Yhim H, Hetjens S, Weiß C, Rasmussen CL, Urbute A, Verdoodt F, Kjaer SK, Reuschenbach M, Goetghebeur E, von Knebel Doeberitz M, Arbyn M, Priggea E. Prognostic value of high-risk human papillomavirus DNA and p16INK4a immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis. Eur J Cancer 2021, 157; 165-178 doi: doi.org/10.1016/j.ejca.2021.07.041
  • Oštrbenk Valenčak A, Bertram A, Gröning A, Poljak M. Comparison of the clinical and analytical performance of Alinity m HR HPV and cobas 4800 HPV assays in a population-based screening setting.Journal of Clinical Virology Volume 140, July 2021, 104851. doi: doi.org/10.1016/j.jcv.2021.104851
  • Pauw de H, Donders G, Weyers S, De Sutter P, Doyen J, Tjalma WAA, et al. Cervical cancer screening using HPV tests on self-samples: attitudes and preferences of women participating in the VALHUDES study. Arch Public Health. 2021 Aug 30;79(1):155.
  • Rezhake R, Wang Y, Chen F, Hu SY, Zhang X, Cao J, et al. Clinical evaluation of p16INK4a immunocytology in cervical cancer screening: A population-based cross-sectional study from rural China. Cancer Cytopathol. 2021;129(9):679–92.
  • Schulte-Frohlinde R, Georges D, Clifford GM, Baussano I. Predicting cohort-specific cervical cancer incidence from population-based HPV prevalence surveys: a worldwide study. Am J Epidemiol. 2021 Oct 15. doi: doi.org/10.1093/aje/kwab254
  • Simoens C, Gorbaslieva I, Gheit T, Holzinger D, Lucas E, Ridder R, et al. HPV DNA genotyping, HPV E6*I mRNA detection, and p16INK4a/Ki-67 staining in Belgian head and neck cancer patient specimens, collected within the HPV-AHEAD study. Cancer Epidemiol. 2021 Jun 1;72:101925.
  • Stanczuk GA, Currie H, Forson W, Baxter G. Lawrence J, Wilson A, Palmer T, Arby M, Cushieri K. Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the PaVDaG study. IJC 2021. doi: https://doi.org/10.1002/ijc.33888
  • Strojan Fležar M, Nedelko N, Poljak M, Oštrbenk Valencak A, Gutnik H. Stratified Mucin-Producing Intraepithelial Lesion (SMILE) of the Uterine Cervix: High-Risk HPV Genotype Predominance and p40 Immunophenotype. Cells 2021, 10, 2039.doi: 10.3390/cells10082039.
  • Suomenrinne-Nordvik A, Vänskäa S. The confounding effect of multi-type human papillomavirus infections on type-specific natural history parameter identification. Epidemics Volume 36, September 2021, 100468 doi.org/10.1016/j.epidem.2021.100468
  • van de Ven PM, Bassi A, Berkhof J. Comparing the sensitivities of two screening tests in nonblinded randomized paired screen-positive trials with differential screening uptake. Statistics in Medicine 2021. doi: doi.org/10.1002/sim.9215.
  • Van Keer S, Peeters E, Vanden Broeck D, De Sutter P, Donders G, Doyen J, et al. Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol. Gynecol Oncol. 2021 Jun 23;162(3):575–83.
  • Verhoef L, Bleeker MCG, Polman N, Steenbergen RDM, Meijer CJLM, Melchers WJG, Bekkers RL, Molijn AC, Quint WG, van Kemenade FJ, Berkhof J, Heideman DAM. Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: Results from a Dutch primary HPV-based screening cohort. Int J Cancer. 2021 Sep 24. doi: 10.1002/ijc.33820.
  • Vink FJ, Dick S, Heideman DAM, de Strooper L, Steenbergen RDM, Lissenberg-Witte BLW, DNTP group, Floore A, Bonde JH, Oštrbenk Valenčak A, Poljak M, Petry KU, Hillemans P, van Trommel NE, Berkhof J, Bleeker MCG, Meijer CLJM, Classification of high‐grade CIN by p16ink4a, Ki‐67, HPV E4 and FAM19A4/miR124‐2 methylation status demonstrates considerable heterogeneity with potential consequences for management. Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33566.
  • Wang J, Elfstrom K, Borgfeldt C, Dillner J. A pilot study of risk-stratified cervical cancer screening [version 2; peer review: 2 approved]. Open Research Europe [Internet]. 2021;1(84). Available from: https://open-research-europe.ec.europa.eu/articles/1-84
  • Yuill S, Velentzis LS, Smith M, Egger S, Wrede CD, Bateson D, Arbyn M, Canfell K. The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes. Hum Vaccin Immunother 2021. Oct 3;17(10):3562-3576. doi: 10.1080/21645515.2021.1936860.

2020

  • Arbyn M, Bruni L, Kelly D, Basu P, Poljak M, Gultekin M, Bergeron C, Ritchie D, Weiderpass E. ‘Tackling Cervical Cancer in Europe amidst the COVID-19 Pandemic’. The Lancet Public Health 5, no. 8 (1 August 2020): e425.
  • Arbyn M, Gondry J, Nieminen P. Long-term prediction of failure after treatment of cervical precancer. BJOG. 2020 Feb;127(3):388. doi: 10.1111/1471-0528.16023.
  • Arbyn M, Rezhake R, Yuill S, Canfell K. Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence. Br J Cancer. 2020 May;122(11):1577-1579. doi: 10.1038/s41416-020-0787-9.
  • Arbyn M, Weiderpass E, Bruni L, de Sanjosé, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6.
  • Bonde JH, Pedersen H, Quint W, Xu L, Arbyn M, Ejegod DM. Clinical and Analytical Performance of the BC Onclarity HPV assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework. J Clin Microbiol . 2020 Jan 28;58(2):e01518-19. doi: 10.1128/JCM.01518-19.
  • Bray F, Laversanne M, Weiderpass E, Arbyn M. ‘Geographic and Temporal Variations in the Incidence of Vulvar and Vaginal Cancers’. International Journal of Cancer 147, no. 10 (2020): 2764–71. https://doi.org/10.1002/ijc.33055.
  • Ciavattini A, Delli Carpini G, Giannella L, Arbyn M, Kyrgiou M, Joura EA, Sehouli J, Carcopino X, Redman CW, Nieminen P, Cruickshank M, Gultekin M. European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. Int J Gynecol Cancer. 2020 Aug;30(8):1097-1100. doi: 10.1136/ijgc-2020-001617.
  • Ejegod, Ditte Møller, Mona Hansen, Irene Kraus Christiansen, Helle Pedersen, Wim Quint, Lan Xu, Marc Arbyn, and Jesper Bonde. ‘Clinical Validation of the Cobas 4800 HPV Assay Using Cervical Samples in SurePath Medium under the VALGENT4 Framework’. Journal of Clinical Virology 128 (1 July 2020): 104336. https://doi.org/10.1016/j.jcv.2020.104336.
  • Inturrisi F, Bogaards JA, Heideman DAM, Meijer CJLM, Berkhof J. Risk of cervical intraepithelial neoplasia grade 3 or worse in HPV-positive women with normal cytology and five-year type concordance: a randomized comparison. Cancer Epidemiol Biomarkers Prev 2020 Dec 8 doi:10.1158/1055-9965.EPI-20-1336
  • Inturrisi F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA, Ronco G, Meijer CJLM, Berkhof J. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer. Int J Cancer. 2020 Jul 14. doi: 10.1002/ijc.33207.
  • Kalliala I, Athanasiou A, Veroniki AA, Galanti G, Efthimiou O, Raftis N, Bowden S, Paraskevaidi M, Aro K, Arbyn M, Bennet P, Nieminen P, Parakevaidis E, Kyrgiou M. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann Oncol 2020 Feb;31(2):213-227. doi: 10.1016/j.annonc.2019.11.004.
  • Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, Kim J, Poljak M, Nieminen P, Sasieni P, Kesic V, Cuzick J, Gultekin M. Cervical screening: ESGO- EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 2020 Aug;123(4):510-517. doi: 10.1038/s41416-020-0920-9.
  • Latsuzbaia A, Wienecke-Baldacchino A, Tapp J, Arbyn M, Karabegović I, Chen Z, et al. Characterization and Diversity of 243 Complete Human Papillomavirus Genomes in Cervical Swabs Using Next Generation Sequencing. Viruses. 2020 Dec 14;12(12).
  • Louvanto K, Eriksson T, Gray P, Apter D, Baussano I, Bly A, Harjula K, Heikkila K, Hokkanen M, Huhtinen L, Ikonen M, Karttunen H, Nummela M, Söderlund-Strand A, Veivo U, Dillner J, Elfstöm M, Nieminen P, Lehtinen M. Baseline findings and safety of of infrequent of frequent screening of human papillomavirus vaccinated women. International Journal of Cancer. 2020 Jul 15;147(2):440-447. doi: 10.1002/ijc.32802.
  • Nowakowski A, Arbyn M, Turkot MH, Wieszczy P, Milosz K, Kaminski M, Didkowska J, Bidzinski M, Oleszewski W, Wielgos M, Krzakowski M, Kuchar E, Walewski J. A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. Eur J Cancer Prev 2020 Mar;29(2):157-164. doi: 10.1097/CEJ.0000000000000528.
  • Peeters E, Cornet K, Devroey D, Arbyn M. ‘Efficacy of Strategies to Increase Participation in Cervical Cancer Screening: GPs Offering Self-Sampling Kits for HPV Testing versus Recommendations to Have a Pap Smear Taken - A Randomised Controlled Trial’. Papillomavirus Research 9. https://doi.org/10.1016/j.pvr.2020.100194. Corrigendum: doi: 10.1016/j.pvr.2020.100201
  • Poljak M, Oštrbenk Valenčak A, Gimpelj Domjanič G, Xu L, Arbyn M. ‘Commercially Available Molecular Tests for Human Papillomaviruses: A Global Overview’. Clinical Microbiology and Infection, 2 April 2020. https://doi.org/10.1016/j.cmi.2020.03.033.
  • Rezhake R, Chen F, Hu S, Zhao X, Zhang X, Cao J, Qiao Y, Zhao F, Arbyn M. ‘Triage Options to Manage High-Risk Human Papillomavirus-Positive Women: A Population-Based Cross-Sectional Study from Rural China’. International Journal of Cancer 147, no. 8 (2020): 2053–64. https://doi.org/10.1002/ijc.33001.
  • Robles C, Bruni L, Acera A, Riera JC, Prats L, Poljak M, Mlakar J, Ostrbenk Valencak A, Eriksson T, Lethinen M, Louvanto K, Hortlund M, Dillner J, Faber MT, Munk C, Kjaer SK, Petry KU, Denecke A, Xu L, Arbyn M, Cadman L, Cuzick J, Dalstein V, Clavel C, de Sanjosé S, Bosch FX. Determinants of Human Papillomavirus Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. Am J Prev Med 2020 Dec 24;S0749-3797(20)30434-7. doi: 10.1016/j.amepre.2020.08.032.
  • Tagliabue M, Mena M, Maffini F, Gheit T, Quirós Blasco B, Holzinger D, Tous S, Scelsi D, Riva D, Grosso E, Chu F, Lucas E, Ridder R, Rrehm S, Bogers JP, Lepanto D, Lloveras Rubio B, Kumar RV, Gangane N, Clabero O, Pawlita M, Anantharaman D, Pillai MR, Brennan P, Sankaranarayanan R, Arbyn M, Lombardi F, Taberna M, Gandini S, Chiesa F, Ansarin M, Alemany L, Tommasino M, Chiocca S and the HPV-AHEAD Study Group. Role of Human Papillomavirus Infection in Head and Neck Cancer in Italy: The HPV-AHEAD Study. Cancers 2020, 12(12), 3567; https://doi.org/10.3390/cancers12123567.
  • Urbute A, Rasmussen CL, Belmonte F, Obermueller T, Prigge E, Arbyn M, Verdoodt F, Kjaer S. Prognostic Significance of HPV DNA and p16 INK4a in Anal Cancer: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev 2020 Apr;29(4):703-710. doi: 10.1158/1055-9965.EPI-19-1259.
  • Weyers S, Garland SM, Cruickshank M, Kyrgiou M, Arbyn M. ‘Cervical Cancer Prevention in Transgender Men: A Review’. BJOG: An International Journal of Obstetrics & Gynaecology (2020). https://doi.org/10.1111/1471-0528.16503.
  • Xu L, Ostrbenk Valencak A, Poljak M, Arbyn M. Evalaution and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 framework. J Clin Microbiol 2020 May 26;58(6):e00234-20. doi: 10.1128/JCM.00234-20.

Other publications